Please ensure Javascript is enabled for purposes of website accessibility

Novavax Starts Phase 2 Coronavirus Vaccine Clinical Trial

By Brian Orelli, PhD - Aug 24, 2020 at 7:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech moves one step closer to hopefully launching NVX-CoV2373.

Novavax (NVAX -2.68%) is behind the leaders in the race to develop a coronavirus vaccine to prevent COVID-19, but the biotech continues to trot along. On the heels of positive phase 1 data earlier this month, the biotech started the phase 2 portion of its phase 1/2 clinical trial testing its coronavirus vaccine NVX-CoV2373.

The new study will enroll up to 1,500 subjects, substantially more than the 131 subjects enrolled in the phase 1 study. The phase 2 portion also expands the potential ages of participants from a range of 18 to 59 in phase 1 to a range of 18 to 84 for the phase 2 study.

Since older adults are especially vulnerable if they catch COVID-19, its important for a vaccine to be both safe and able to generate an immune response in the older adults. To get the answer quickly, Novavax plans to enroll half of the clinical trial with older adults, aged 60 to 84.

Pfizer (PFE -1.18%) and BioNTech (BNTX 1.48%) recently demonstrated that their coronavirus vaccine, BNT162b2, was able to generate antibodies in older adults 65 to 85. The levels weren't as high as younger subjects, but the antibody levels were still higher than levels seen in patients who had recovered from COVID-19.

Gloved hands giving an injection into a shoulder

Image source: Getty Images.

Novavax's investors will have to wait until the fourth quarter for interim data on antibody levels and safety of the vaccine from the phase 2 study. That's around the same time Pfizer and BioNTech, AstraZeneca, and Moderna expect to have initial phase 3 data, putting Novavax a few months behind the current leaders.

How much Novavax's slower pace hurts the biotech will ultimately be determined by the safety and efficacy of all the vaccines, as well as how quickly the front-runners can ramp up manufacturing to meet global demand.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$60.27 (-2.68%) $-1.66
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.27 (-1.18%) $0.59
BioNTech SE Stock Quote
BioNTech SE
BNTX
$183.11 (1.48%) $2.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.